Cancel Continue. Add to watchlist Add to portfolio Add an alert. Save Clear. Henceforth we will be re-allotting our funds, amounting to 11 million euros before the discontinuation of the REFRESH study, to the development of new innovative molecules in unmet therapeutic domains," adds Benoit Gueugnon, Quantum Genomics Chief Financial Officer. All questions can be sent to: contact quantum-genomics. LifeSci USA. Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Add to Your Portfolio New portfolio. All rights reserved.